Hence, negative regulation of NLRP3 inflammasome activity is essential for controlling epileptogenesis and reducing seizures (Meng et al., 2014; Jang et al., 2016; Lenart et al., 2016; Wang et al., 2017), and may therefore be a target for the treatment of epilepsy. The gene discussed is NLRP3; the disease is epilepsy.